Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
N/A
1(25.0%)
Phase 1
1(25.0%)
4Total
Phase 2(2)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01060878Phase 2Completed

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

Role: lead

NCT01306422Not ApplicableCompleted

Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)

Role: collaborator

NCT00875316Phase 1Completed

Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients

Role: lead

NCT00130429Phase 2Completed

Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease

Role: lead

All 4 trials loaded